Asieris’ CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

China, March, 3, 2026 — Asieris Pharmaceuticals (Stock Code: 688176.SH), a global innovative pharmaceutical company focused on genitourinary tumors and women’s health, announced today that its core product APL-1702 (trade name: CEVIRA®, Hexaminolevulinate Hydrochloride Ointment Photodynamic Therapy System), has received the Drug Registration Certificate from China’s National Medical Products Administration (NMPA) for its commercial launch. […] The post Asieris’ CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions appeared first on Asieris Pharmaceu